Show Summary Details
Page of

HPV vaccination in the developing world 

HPV vaccination in the developing world
HPV vaccination in the developing world

Rengaswamy Sankaranarayanan

and Catherine Sauvaget

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 20 November 2017

• Four-fifths of the cervical cancer burden is in the developing world where there is a lack of effective screening. • The potential to reduce cervical cancer by human papilloma virus (HPV) vaccination in developing countries is challenged by cost and lack of effective vaccine delivery platforms for children and adolescents. • Other challenges include the following: • Sensitivities of using a vaccine preventing an STI in girls • Lack of awareness, public demand, and political will • Lack of coordination between cancer control, sexual/reproductive health, and vaccine delivery services. • Local production of vaccines at reduced cost, logistically feasible efficacious vaccine regimes, and strengthening vaccine delivery infrastructure for children and adolescents will be required for successful HPV vaccination in developing countries. •

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.